uuid:
  -
    value: 872cdc6a-def1-4f7f-8906-5db5f3725563
langcode:
  -
    value: und
type:
  -
    target_id: case_series
    target_type: node_type
    target_uuid: 0ea0fe3a-e616-4d45-88b7-f6bb126fd852
revision_timestamp:
  -
    value: '2016-07-27T22:05:41+00:00'
    format: 'Y-m-d\TH:i:sP'
revision_uid:
  -
    target_type: user
    target_uuid: 7f2b027c-635a-47bd-9500-94902c2d3670
revision_log: {  }
status:
  -
    value: true
uid:
  -
    target_type: user
    target_uuid: 7f2b027c-635a-47bd-9500-94902c2d3670
title:
  -
    value: 'Benecol: Raisio''s Global Nutriceutical'
created:
  -
    value: '2016-07-27T22:05:41+00:00'
    format: 'Y-m-d\TH:i:sP'
changed:
  -
    value: '2016-07-27T22:05:41+00:00'
    format: 'Y-m-d\TH:i:sP'
promote:
  -
    value: false
sticky:
  -
    value: false
default_langcode:
  -
    value: true
revision_translation_affected:
  -
    value: true
path:
  -
    alias: /faculty-and-research/case-series/id/a06-99-0004
body:
  -
    value: '<div class="field field-name-body field-type-text-with-summary field-label-above"><div class="field-items"><div class="field-item even"><p>Raisio (Finland) is in the final stages of introducing its revolutionary product, Benecol, to the global market. Benecol, when ingested on a daily basis (for example as an additive to margarine), reduces LDL cholesterol levels in the human body by 10-15%. After a successful debut in Finland in the fall of 1996, Raisio has concluded a global marketing agreement with Johnson &amp; Johnson''s (US) McNeil Consumer Products Group. The product has now, just prior to introduction in the United States, run into regulatory objections from the Food &amp; Drug Administration (FDA). The question is whether the current strategy is really in the best interests of shareholders, and what the market should do in valuing the prospects for this current hot stock.</p><p>&nbsp;</p></div></div></div>'
    format: basic_html
    processed: ''
    summary: ''
    summary_processed: ''
field_case_number:
  -
    value: A06-99-0004
field_case_page_length:
  -
    value: '21 pages'
field_case_series_author:
  - {  }
field_case_series_date: {  }
field_case_series_image: {  }
field_case_series_industry:
  -
    target_type: taxonomy_term
    target_uuid: a3e2bcd3-f4a0-4df0-b1c9-478df5e4b3c5
field_case_series_year:
  -
    value: '1999-01-01'
field_case_setting:
  -
    value: 'Finland, United States, 1998/99'
field_case_source:
  -
    value: 'Field case'
field_case_subject:
  -
    target_type: taxonomy_term
    target_uuid: 5d6eba99-f8ab-4ad8-88bc-9d20e713d129
field_fields:
  -
    target_type: taxonomy_term
    target_uuid: 855c0ea6-5225-49c7-a911-037ed2bad950
field_teaching:
  -
    value: "The case focuses on the complexities of penetrating global markets when the product is difficult to classify as a food, dietary supplement, or pharmaceutical, when time is of the essence, and value fleeting. The market penetration strategy proposed by McNeil Consumer Products is controversial, and if the United States Food and Drug Administration chooses to block the product's entry, Raisio has risked much. In addition to the complex product definition and marketing strategy issues, the case allows a very detailed analysis of how the parent company Raisio may profit from the global introduction of Benecol, and how the analysts in the marketplace value a firm like Raisio.\r\n\r\n"
_content_sync:
  entity_type: node
  entity_dependencies:
    user:
      - user.user.7f2b027c-635a-47bd-9500-94902c2d3670
    taxonomy_term:
      - taxonomy_term.case_series_industry.a3e2bcd3-f4a0-4df0-b1c9-478df5e4b3c5
      - taxonomy_term.case_series_categories.5d6eba99-f8ab-4ad8-88bc-9d20e713d129
      - taxonomy_term.case_series_fields.855c0ea6-5225-49c7-a911-037ed2bad950
